TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1827340

Group type: EXPERIMENTAL
Intervention: Extradural sufentanil (ES)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (IS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous sufentanil (IVS)
Number of subjects: 31
Study: 6452825

Group type: EXPERIMENTAL
Intervention: Nonabsorbable multifilament suture material
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Nonabsorbable monofilament suture material
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Long‐term absorbable suture material
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (nonabsorbable multifilament and monofilament suture materials)
Number of subjects: 161
Study: 30913051

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 40
Study: 27964912

Group type: EXPERIMENTAL
Intervention: Upper limb massage (2-minute massage before venipuncture)
Number of subjects: 80
Study: 26009712

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg tablets thrice daily for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard of care (cetirizine 10 mg OD and calamine)
Number of subjects: 24
Study: 23841586

Group type: EXPERIMENTAL
Intervention: Video education and information leaflets
Number of subjects: 61

Group type: COMPARATOR
Intervention: Information leaflets alone
Number of subjects: 61
Study: 21999640

Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin + insulin glargine (TI+G)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Premixed aspart insulin 70/30
Number of subjects: 618
Study: 19735497

Group type: EXPERIMENTAL
Intervention: NIDCAP (treatment, E)
Number of subjects: 107
Study: 16443446

Group type: EXPERIMENTAL
Intervention: Reading for translation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading for repetition
Number of subjects: 0
Study: 12606844

Group type: EXPERIMENTAL
Intervention: Flupenthixol (mean daily dose 6.6 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone (mean daily dose 3.6 mg/day)
Number of subjects: 0
Study: 10669447

Group type: EXPERIMENTAL
Intervention: Amalthea Project
Number of subjects: 161

Group type: COMPARATOR
Intervention: General practitioner care
Number of subjects: 161
Study: 10173126

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg (type IIa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin 20 mg (type IIa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg (type IIb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin 20 mg (type IIb)
Number of subjects: 0
Study: 8453546

Group type: EXPERIMENTAL
Intervention: Phosphorus-32 as primary adjuvant treatment
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Phosphorus-32 as consolidating therapy after second-look surgery
Number of subjects: 313

Group type: COMPARATOR
Intervention: Phosphorus-32 (randomized group)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Phosphorus-32 treatment
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Phosphorus-32 scintigraphy
Number of subjects: 313
Study: 2937598

Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 160 mg twice a day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nitrendipine (5 to 20 mg twice a day)
Number of subjects: 19
Study: 30227833

Group type: EXPERIMENTAL
Intervention: Dietary and physical activity lifestyle intervention
Number of subjects: 1555
Study: 26689302

Group type: EXPERIMENTAL
Intervention: Personalized feedback interventions (PFIs)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 212
Study: 24516038

Group type: EXPERIMENTAL
Intervention: octreotide LAR 30 mg intramuscularly every 4 weeks
Number of subjects: 139

Group type: COMPARATOR
Intervention: Physician's treatment of choice in case of diarrhea
Number of subjects: 139
Study: 22310472

Group type: EXPERIMENTAL
Intervention: Higher protein content formula (HP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lower protein content formula (LP)
Number of subjects: 41
Study: 19579144

Group type: EXPERIMENTAL
Intervention: Rolling-over maneuver (ROM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Canalith repositioning maneuver (CRP)
Number of subjects: 22
Study: 18827176

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day (titrated to 10 mg if BP goal not achieved)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 16179197

Group type: EXPERIMENTAL
Intervention: sEMG and 3-D motion analysis systems
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (asymptomatic male subjects)
Number of subjects: 46
Study: 12525531

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 11392163

Group type: EXPERIMENTAL
Intervention: OAT-omeprazole (2 x 20 mg), amoxycillin (2 x 1000 mg), tinidazole (2 x 500 mg)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: OAC-omeprazole (2 x 20 mg), amoxycillin (2 x 1000 mg), clarithromycin (2 x 250 mg)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: OAC group (smokers)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: OAT group (drinkers)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: OAT group (non-drinkers)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: OAC group (non-drinkers)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Combined analysis (OAT + OAC)
Number of subjects: 142
Study: 8842111

Group type: EXPERIMENTAL
Intervention: Arteflene (25 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mefloquine (15 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Arteflene
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 41
Study: 1503438

Group type: COMPARATOR
Intervention: S-1108 (200 mg TID for 8 days)
Number of subjects: 0
Study: 6147640

Group type: EXPERIMENTAL
Intervention: CHAP-5
Number of subjects: 186

Group type: COMPARATOR
Intervention: Hexa-CAF
Number of subjects: 186
Study: 29799960

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Adalimumab (80 mg week 0, 40 mg week 1, then every 2 weeks)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1829
Study: 26884585

Group type: EXPERIMENTAL
Intervention: Apatinib 850 mg once daily
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 24397690

Group type: EXPERIMENTAL
Intervention: Arm exercise during cold water immersion at 15°C (CW15+AE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cold water immersion at 15°C (CW15)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arm exercise during thermoneutral immersion at 34°C (TW34+AE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Non-immersed arm exercise (AE)
Number of subjects: 8
Study: 22356732

Group type: EXPERIMENTAL
Intervention: Breathe Easier Online (BEO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 42
Study: 20831723

Group type: EXPERIMENTAL
Intervention: Trail-walking exercise (TWE) program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Walking (W) group
Number of subjects: 60
Study: 18669959

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 80
Study: 15989829

Group type: EXPERIMENTAL
Intervention: Relaxation techniques (RT) combined with conventional treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 104
Study: 12466335

Group type: EXPERIMENTAL
Intervention: 50 mg androstenedione
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (0 mg androstenedione)
Number of subjects: 30
Study: 10466913

Group type: EXPERIMENTAL
Intervention: Rhesus‐human reassortant rotavirus tetravalent vaccine (RRV‐TV)
Number of subjects: 0
Study: 8554942

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g kg‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g kg‐1) + Caffeine (400 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1939687

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate (sedative medication) prescribed in a reducing dose over the first 10 days of extinction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extinction alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered double-blind
Number of subjects: 0
Study: 7006381

Group type: EXPERIMENTAL
Intervention: Methicillin sodium
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nafcillin sodium
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 149
Study: 31988384

Group type: EXPERIMENTAL
Intervention: Ai Chi
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional water-based exercise
Number of subjects: 20
Study: 30322794

Group type: EXPERIMENTAL
Intervention: Hypoglycemia During Hospitalization (HyDHo) scoring system
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: HyDHo scoring system with a score of ≥9
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: HyDHo scoring system
Number of subjects: 300
Study: 28648803

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice-daily)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 313
Study: 25078717

Group type: EXPERIMENTAL
Intervention: Real occipital transcutaneous electrical stimulation (OTES)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham occipital transcutaneous electrical stimulation (OTES)
Number of subjects: 160
Study: 24177376

Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon and ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peginterferon and ribavirin
Number of subjects: 0
Study: 21184620

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Indacaterol 600 μg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 18388156

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 0
Study: 17579541

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Befriending (Control)
Number of subjects: 90
Study: 15163137

Group type: EXPERIMENTAL
Intervention: Enhanced communication with direct-to-member postcards
Number of subjects: 1930

Group type: COMPARATOR
Intervention: Standard contract changes
Number of subjects: 1930
Study: 11460023

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 gel (52.5 mg)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 11020194

Group type: EXPERIMENTAL
Intervention: Height of 10 m 22 cm with eyes open and closed (acrophobic group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Height of 1 m and 2 m with eyes open and closed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Guided to the roof with eyes closed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eyes open after eyes closed measurement
Number of subjects: 30
Study: 10423625

Group type: EXPERIMENTAL
Intervention: edrophonium (1 mg/kg) and atropine (0.01 mg/kg) reversal (E/A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 30
Study: 8475472

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without acamprosate)
Number of subjects: 0
Study: 3860788

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (16 mg diluted in 40 mL of saline)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline only (control)
Number of subjects: 102
Study: 30318916

Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (regular socks)
Number of subjects: 20
Study: 30098513

Group type: EXPERIMENTAL
Intervention: Hostile marital interactions
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Hostile marital interactions with mood disorder history
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher LBP
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher sCD14
Number of subjects: 86
Study: 29469430

Group type: EXPERIMENTAL
Intervention: Conventional nursing plus solution focused approach
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 53
Study: 24895288

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23254795

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 208
Study: 20593555

Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CPP-ACP with 900 ppm fluoride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saliva (control)
Number of subjects: 45
Study: 18514729

Group type: EXPERIMENTAL
Intervention: Prednisolone (35 mg once a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 120
Study: 15793255

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 2343

Group type: EXPERIMENTAL
Intervention: Troglitazone (after withdrawal)
Number of subjects: 2343
Study: 11922229

Group type: EXPERIMENTAL
Intervention: Inolter
Number of subjects: 60
Study: 10417579

Group type: EXPERIMENTAL
Intervention: Topical onion gel extract
Number of subjects: 17

Group type: COMPARATOR
Intervention: Topical emollient ointment (petrolatum based)
Number of subjects: 17
Study: 8824652

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine b.d.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole o.m.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1904681

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (2 months before hysterectomy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no agonist)
Number of subjects: 50
Study: 31455700

Group type: EXPERIMENTAL
Intervention: Proactive case detection by CHWs with daily home visits and doorstep services
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional approach to iCCM service delivery with services provided exclusively out of a fixed community health site
Number of subjects: 137
Study: 28560470

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 25263215

Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23369425

Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Concentric (CON) training
Number of subjects: 30
Study: 21233468

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (S‐tDCS)
Number of subjects: 8
Study: 19584192

Group type: EXPERIMENTAL
Intervention: Add teriparatide (20 microg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switch to teriparatide (20 microg/d)
Number of subjects: 0
Study: 18181517

Group type: EXPERIMENTAL
Intervention: Polymethoxyethylacrylate-coated circuits + Leukocyte filters
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control: Uncoated circuits
Number of subjects: 120
Study: 15019156

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day for one year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11464352

Group type: EXPERIMENTAL
Intervention: Water-diluted 0.25% lidocaine
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Water-diluted 0.25% mepivacaine
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Water-diluted 0.2% lidocaine
Number of subjects: 61
Study: 9669136

Group type: EXPERIMENTAL
Intervention: 2% Ketoconazole shampoo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% Minoxidil therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmedicated shampoo
Number of subjects: 0
Study: 7520956

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil and intravenous folinic acid Days 1-6 after operation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 26
Study: 3180905

Group type: EXPERIMENTAL
Intervention: Erythromycin‐propionate‐N‐acetylcysteinate (EPAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Erythromycin stearate (ES)
Number of subjects: 30
Study: 4212040

Group type: EXPERIMENTAL
Intervention: Gentamicin plus daily granulocyte transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin alone
Number of subjects: 0
Study: 30553440

Group type: EXPERIMENTAL
Intervention: Training group (tuck-and-roll strategy)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 14
Study: 28001306

Group type: EXPERIMENTAL
Intervention: Doxapram (plasma concentration 1,000‐3,500 ng/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alfentanil (plasma concentration 100‐200 ng/mL)
Number of subjects: 0
Study: 26302453

Group type: EXPERIMENTAL
Intervention: Just-in-time (JiT) instructions with Combat Application Tourniquet (C-A-T)
Number of subjects: 194

Group type: COMPARATOR
Intervention: No instructions (Control)
Number of subjects: 194
Study: 24253812

Group type: EXPERIMENTAL
Intervention: Low SMUG1 mRNA expression
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low SMUG1 protein expression
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low SMUG1 protein expression in ER+ cohort receiving adjuvant endocrine therapy
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low SMUG1 protein expression in ER- cohort receiving adjuvant chemotherapy
Number of subjects: 249
Study: 21704237

Group type: EXPERIMENTAL
Intervention: Extended-release tramadol/acetaminophen (tramadol 75 mg/acetaminophen 650 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate-release tramadol/acetaminophen (tramadol 37.5 mg/acetaminophen 325 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations (ER and IR)
Number of subjects: 12
Study: 19565043

Group type: EXPERIMENTAL
Intervention: Functional constipation in adults with a BMI > 25
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Functional constipation in adults
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Functional constipation in low educated women
Number of subjects: 459
Study: 16384765

Group type: EXPERIMENTAL
Intervention: Bexarotene gel 1% with narrowband UVB phototherapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle gel with narrowband UVB phototherapy
Number of subjects: 9
Study: 12771113

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate)
Number of subjects: 4532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4532

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 4532
Study: 10852275

Group type: EXPERIMENTAL
Intervention: 240 mg i.v. pulse of methylprednisolone followed by 0.7 mg/kg/day oral prednisone (Group 1)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 0.7 mg/kg/day prednisone without an i.v. pulse (Group 2, controls)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 240 mg i.v. pulse of methylprednisolone followed by 0.5 mg/kg/day prednisone (Group 3)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Corticosteroid resistance
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Corticosteroid related side effects
Number of subjects: 164
Study: 9089425

Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF) 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF) 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF) 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF)
Number of subjects: 12
Study: 8385176

Group type: EXPERIMENTAL
Intervention: Human BNP (2 pmol/kg per min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 6
Study: 3643648

Group type: EXPERIMENTAL
Intervention: Oral course of pivampicillin/pivmecillinam (PAPM)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Parenteral cefotaxime (CFT)
Number of subjects: 261
Study: 31019486

Group type: EXPERIMENTAL
Intervention: Epley maneuver without intervals between positions (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epley maneuver with 3 min intervals between positions (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epley maneuver with intervals (group B)
Number of subjects: 40
Study: 28693484

Group type: EXPERIMENTAL
Intervention: Multi-component intervention involving 12 months of £20 vouchers for physical activities, peer mentor scheme, advocacy meetings
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control schools continuing usual practice
Number of subjects: 7
Study: 25837829

Group type: EXPERIMENTAL
Intervention: ombitasvir plus paritaprevir plus ritonavir with ribavirin
Number of subjects: 135

Group type: COMPARATOR
Intervention: ombitasvir plus paritaprevir plus ritonavir without ribavirin
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: ribavirin-containing regimen
Number of subjects: 135